Nereid Therapeutics

Nereid Therapeutics is an ATP company discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and resulting biomolecular condensates.

Nereid Therapeutics is translating the therapeutic promise of biomolecular condensates -- from physics to physicians.

Nereid Therapeutics was founded in 2020 by Apple Tree Partners, with Clifford P. Brangwynne. The company is headquartered in Boston, Massachusetts.

 

Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases. 

 

The Nereid drug discovery platform builds from a set of proprietary technologies, developed in the Brangwynne Lab at Princeton, that utilize advanced microscopy and computer vision to enable the precise measurement, interrogation, and control of phase separation in living mammalian cells.

 

Nereid Therapeutics has raised $50M in a Series A funding round on Nov 16, 2020. The financing was backed by Apple Tree Partners (ATP), a leading life sciences venture firm.

 

 

  • Year founded: 2020
  • Funding Info: $50M over 1 Round (Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Boston
  • State: Massachusetts
  • Country: United States
Related businesses